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ABSTRACT
Brief Report
The aim of this study was to correlate ABO groups with plasma levels of factor VIII
(FVIII), von Willebrand factor (VWF:Ag), and ristocetin cofactor (VWF:RCo). Serological
and molecular tests defined blood groups from 114 donors (10 AA, 10 BB, 10 AB,
10 AO1, 10 BO1,16 O1O1, 20 A2O1, 20 A2B, 4 A3O1, 3 AxO1, and 1 BelO1). The levels of
VWF:Ag, FVIII and VWF:RCo  observed in rare subgroups (A3O1, AxO1, BelO1) were simi-
lar to the values found in  the O1O1 group. However, levels of these factors were sig-
nificantly higher in A2O1 donors than in O1O1 donors (VWF:Ag p=0.01; FVIII p=0.04;
VWF:RCo p<0.001). Strong correlations were demonstrated between plasma levels
of VWF:Ag and FVIII (R=0.77; p=0.001) and  between VWF:Ag and VWF:RCo (R=0.75;
p=0.001).
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on Willebrand factor (VWF) is a multi-
meric glycoprotein whose circulating
plasma levels vary significantly within
and between individuals. These variations
have been associated with ABO blood type,
estrogen levels, age and stress.1-4 In particular,
ABO blood type exerts a major effect on plas-
ma VWF levels. Recent studies have demon-
strated that  individuals carrying one O allele
(AO and BO) have significantly lower plasma
levels of VWF and FVIII than  those carrying
no O allele (AA, AB and BB).5 The antigens
of the ABO system consist of complex carbo-
hydrate molecules. The A and B alleles
encode A and B glycosyltransferase, which
convert H antigen into A or B determinants.
Group O individuals lack transferase enzy -
mes and, consequently, continue to express H
antigen.6 In addition to the common pheno-
types A1 and A2, numerous phenotypes with
weak expression of A or B antigens have
been found. Most of these phenotypes can be
fitted into the following categories: A3, Ax, Ael,
B3 and Bel. All have enhanced expression of H
antigen.7 O´Donnel et al.,8 described a direct
relationship between ABO genotype, A
transferase expression, and the amount of A
antigen expressed on circulating VWF. The
susceptibility of VWF of blood group O, A, B
and AB to proteolysis by the ADAMTS 13
metalloprotease was investigated and multi-
meric analysis indicated that the rate of VWF
proteolysis differed between blood groups
and was greater for group O VWF than for
non-O VWF.9 The aim of this study was to
correlate ABO groups and rare subgroups
with plasma levels of factor VIII (FVIII), von
Willebrand factor (VWF:Ag), and ristocetin
cofactor (VWF:RCo).
Design and Methods
Samples from 114 blood donors with
known blood groups and subgroups were
submitted to ABO serology and molecular
analysis, VWF:Ag  and FVIII  dosages and ris-
tocetin cofactor assay. The donors were
males with no history of taking drugs. The
age of the donors ranged from 18-60 years
old (median age 32). The donors were instructed regard-
ing the nature and non-compulsory character of the
research, and signed informed consent was obtained prior
to collecting samples. This study was approved by the
Research Ethics Committee of the State University of
Campinas and Brazilian Medical Research Committee.
Blood was drawn by venipuncture into evacuated sili-
conized glass tubes containing 3.2% sodium citrate, in a
ratio of 1:9 with blood, for ristocetin cofactor assay,
VWF:Ag and factor VIII dosages. Blood processing was
completed within 2 hours. Blood samples for ABO serol-
ogy and molecular analysis were collected according to
standard blood banking practice.10
ABO phenotypes were determined by agglutination
and adsorption-elution tests using monoclonal and poly-
clonal anti-A, B and AB antibodies (Asem-NPBI, Itape -
cirica da Serra, São Paulo Brazil; DiaMed SA, Cressier
s/Morat, Suisse; DiaMed Latino América, Lagoa Santa,
Brazil). H antigen was determined using anti–H lectin
from Ulex europaeus (DiaMed Latino América, Lagoa
Santa, Brazil) and the agglutination reaction intensity was
evaluated according to Marsh et al.11 Serum screening for
isoagglutinins and antibodies was performed by tube
agglutination tests at 4°C and 22°C and by standardized
serological procedures with a microtyping system
(DiaMed SA, Cressier s/Morat, Suisse).10 Saliva testing
was performed using a technique described elsewhere.10
Subgroup serologic status was defined according to
Daniels.7
Genomic DNA was extracted from blood conserved
with EDTA using the standard phenol-chloroform tech-
nique. ABO genotyping was performed by polymerase
chain reaction (PCR) amplification of exons 6 and 7 of the
ABO gene, followed by diagnostic restriction enzyme
digestion. Four different primers were used to amplify
two fragments, each spanning a different polymorphic
site of the ABO gene. Primers, exon 6: P1-5´-TGCCAG -
CTCCATGTGACCGC 3´ (sense), P2-5´ TCGCCACTGC-
CTGGGTCTCTAC 3´ (antisense); exon 7: P3-5´ CCGTC-
CGCCTGCCTTGCAG 3´ (sense), P4-5´ TGCCGGCAG -
CCCTCCCAGAG 3’ (antisense). Primers P1/P2 in con-
junction with the restriction enzyme KpnI and BstE Iwere
used to differentiate the O1 allele from the A, B and O2
alleles.12 Primers P3/P4 in conjunction with the restriction
enzyme AluIwere used to differentiate the A2 from the A1
allele. These same primers with the restriction enzyme
MboI were used to discriminate the AX from A1, A2 and A3
alleles.13 A3(3) and Bel(1) serological and genetic molecular
studies were previously described.14,15 The ABO alleles are
named according to the nomenclature used in the Blood
Group Antigen Gene Mutation Database (http://www.bioc.
aecom.yu.edu/bgmut/abo.htm).
Factor VIII coagulant was measured by a one stage
clothing method using a factor-VIII deficient substrate.16
The activity of vWF was measured by ristocetin cofactor
assay – VWF:RCo – (Helena Laboratories, Beaumont,
Texas, USA). VWF:Ag was measured by an enzyme-
linked immunosorbent assay (ELISA) using polyclonal
antiserum (Dako, Denmark). Lyophilised commercial ref-
erence preparations of VWF:Ag, FVIII and VWF:RCo,
standardized against the World Health Organization stan-
dard, were used as the standards in this study.
Statistical analysis
Statistical analysis was performed using Wilcoxon’s
rank sum test and Spearman´s rank correlation. p values
≤0.05 were considered statistically significant. 
Results and Discussion
The ABO serological and genotype distribution were
AA (n=10), BB (n=10), AB (n=10), AO1 (n=10), BO1 (n=10),
O1O1 (n=16), A2O1 (n=20), A2B (n=20), A3O1 (n=4), AxO1
(n=3), and BelO1 (n=1). The antigen H investigation showed
a score of 11 or 12 for O1O1, a score of 0 for AA, BB, AB,
A2B, AO1 and BO1; a score of 7 or 8 for A2O1; and a score
of 10 or 11 for A3O, AxO and BelO.11 The rare subgroups
A3O, AxO and BelO, were considered as single group for the
statistical analysis. Group O individuals and those carrying
this allele had significantly lower levels of VWF:Ag, FVIII
and VWF:RCo than did individuals of groups AA, AB and
BB. The median levels of these factors were lower in sub-
group A2O1 (VWF:Ag=89%;  FVIII=96%; VWF:RCo=99%)
than in subgroups AA, AB and BB (median: VWF:
Ag=120%, p<0.001; FVIII=117%, p<0.001, VWF:
RCo=19%, p<0.001) and A2B (median: VWF:Ag=169%,
p<0.001; FVIII=112%, p<0.001; VWF:RCo=132%,
p=0.001) and higher than in subgroup O1O1 (median:
VWF:Ag=69%, p=0.018; FVIII=75%, p=0.048; VWF:
RCo=65%, p<0.001). The levels of the same factors in
A3O1, AXO1 and BelO1 donors (median: VWF:Ag=75%;
FVIII:C=88%; VWF:RCo=76%) were statistically signifi-
cantly lower than those in groups AA, AB and BB
(VWF:Ag, p<0.001; FVIII, p=0.004; VWF:RCo, p<0.001)
and A2B (VWF:Ag, p<0.001; FVIII, p=0.001; VWF:RCo,
p<0.001) (Figure 1). However, no statistically significant
differences were observed when the results obtained in
rare subgroups were compared with those in O1O1
(VWF:Ag, p=0.49; FVIII p=0.57; VWF:RCo, p=0.23),
AO1/BO1 (median: VWF:Ag=80%, p=0.89; FVIII=89%,
p=0.95; VWF:RCo=86%, p=0.95) and A2O1 for  VWF and
FVIII (VWF:Ag, p=0.66; FVIII, p=0.57). VWF:RCo in A3O1,
AXO1 and BelO1 subgroups was statistically different from
that in subgroup A2O1 (p=0.029). The results also showed
higher VWF levels in A2B individuals (median:
VWF:Ag=169%) than in the AA, AB and BB groups
(p=0.013) (Figure 1A). 
Overall, there was a strong correlation between VWF:Ag
and FVIII levels (R=0.77; p=0.001) and between VWF:Ag
and VWF:RCo levels (R=0.75; p=0.001) (Spearman’s rank
correlation). 
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This study was carried out to assess FVIII, VWF:Ag and
VWF:RCo in 114 healthy male blood donors. It was
restricted to males to avoid possible estrogen-related
effects, although gender differences in FVIII and VWF:Ag
were not seen in  two previous studies of younger popula-
tions.3,17 Our data demonstrated a strong correlation
between VWF:Ag plasma levels and FVIII and also
between VWF:Ag and VWF:RCo. The donors were ABO
genotyped and the results clearly showed a significant
linkage between the ABO locus and VWF antigen
(p=0.001). Subjects with H-antigen-rich blood groups had
significantly lower levels of FVIII and VWF:Ag antigen
than did individuals with H-antigen-poor groups.18 A2O1
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Figure 1 (A,B,C). Box-and-whisker plots representing the circulating levels of von Willebrand factor (VWF:Ag), factor VIII (FVIII) and risto-
cetin cofactor activity (VWF:RCo) in individuals with different blood groups. The graphics present the groups with statistically different
results. The plots show a box defined by the lower and upper quartiles with the median factor dosages represented by a subdivision of
the box. A. VWF:Ag median (%). B. FVIII (%). C. VWF:RCo.
than did AA, AB, BB and A2B subjects and higher levels
than O1O1 subjects. These data corroborate a case-control
study in which group O and A2 individuals, presenting low
levels of FVIII, were considered to have a low risk of
thrombosis, in contrast to group A1, A1B and B1 individu-
als.19 The observation of high VWF:Ag levels in A2B indi-
viduals was unexpected. The antigen H investigation
showed score 0 for A2B, the same value for AA, AB, BB and
also for heterozygous AO and BO groups. The biological
and clinical implications of this observation are unclear.
One interesting finding was that A3O1, AxO1 and BelO1
subgroups had significantly lower VWF:Ag and FVIII lev-
els when compared to the A2B group, but no difference
when compared to O1O1 and A2O1. These subgroups are,
however, rare and thus the study numbers were small
(eight cases).  Previous reports have demonstrated that the
normal range of VWF:Ag found in group O individuals
reaches below 50 IU/dL.8 Unless ABO group-specific
VWF:Ag references ranges are used, normal group O  and
also ABO subgroup individuals could be identifying as
having a level of VWF below the normal reference range
and therefore at  potential risk of bleeding. These results
favor the hypothesis that the expression of H antigen on
VWF is one of the most important determinants of circu-
lating levels of VWF:Ag.8 In conclusion, we demonstrated
that the circulating levels of VWF:Ag and FVIII in subjects
with rare subgroups were similar to those found in group
O individuals. These data could contribute to the diagno-
sis of von Willebrand’s disease and to the evaluation of
thrombophilia in individuals with different ABO sub-
groups.
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